Title : Thromboxane A2 receptor antagonist SQ29548 suppresses the LPS‑induced release of inflammatory cytokines in BV2 microglia cells via suppressing MAPK and NF‑κB signaling pathways.

Pub. Date : 2017 Sep

PMID : 28677768






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Thromboxane A2 receptor antagonist SQ29548 suppresses the LPS-induced release of inflammatory cytokines in BV2 microglia cells via suppressing MAPK and NF-kappaB signaling pathways. SQ 29548 toll-like receptor 4 Mus musculus
2 In the present study, the anti-inflammatory effects of SQ29548 on lipopolysaccharide (LPS)-stimulated BV2 microglial cells and its molecular mechanisms were investigated. SQ 29548 toll-like receptor 4 Mus musculus
3 In vitro studies demonstrated that SQ29548 inhibited LPS-stimulated BV2 activation and reduced the mRNA expression levels of interleukin (IL)-1beta, IL-6, tumor necrosis factor-alpha and inducible NO synthase via inhibition of MAPKs and the NF-kappaB signaling pathway. SQ 29548 toll-like receptor 4 Mus musculus
4 SQ29548 inhibited the LPS-induced inflammatory response by blocking MAPKs and NF-kappaB activation in BV2 microglial cells. SQ 29548 toll-like receptor 4 Mus musculus